130 results match your criteria: "Massachusetts General Hospital – Harvard Medical School[Affiliation]"

Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans.

N Engl J Med

January 2025

From the Department of Pediatrics, Duke University Medical Center, Durham (R.A.G.), and the Departments of Medicine (B.I.F.) and Biochemistry (N.D.P.), Wake Forest University School of Medicine, Winston-Salem - both in North Carolina; the Department of Medicine, University of Nigeria, Nsukka (I.U.), the Department of Medicine, College of Medicine, University of Ibadan, Ibadan (S. Ajayi, Y.R., A.D.A., A. Asinobi, O. Amodu, B.L.S.), the Department of Medicine, University of Ilorin, Ilorin (T.O.), the Department of Medicine, Obafemi Awolowo University, Ile-Ife (F.A.), the Department of Medicine, University of Abuja, Abuja, Nigeria (M. Mamven), the Department of Medicine, College of Medicine, University of Lagos, Lagos (T.A.), the Department of Medicine, College of Medicine, Lagos State University, Ojo (A.S., O. Awobusuyi), the Department of Medicine, Usmanu Danfodiyo University, Sokoto (M. Makusidi), Nnamdi Azikiwe University Teaching Hospital, Nnewi (U.O.), Delta State University Teaching Hospital, Oghara (O.O.), and Aminu Kano Teaching Hospital, Kano (A. Abdu) - all in Nigeria; the Department of Medicine, University of Ghana Medical School (C.O., M. Matekole, V.A., V.B., D.A.), and Noguchi Memorial Institute for Medical Research, University of Ghana (A.N., A.G.), Accra, the Department of Medicine, University of Cape Coast, Cape Coast (I.E.), and Kwame Nkrumah University of Science and Technology, Kumasi (J.P.-R., S. Antwi) - all in Ghana; the Basic Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick (C.A.W.), the Center for Research on Genomics and Global Health, National Human Genome Research Institute (A.A.A.), and the Division of Kidney, Urologic and Digestive Disease, National Institute of Diabetes and Digestive Kidney Diseases (P.L.K.), National Institutes of Health, Bethesda - all in Maryland; the Departments of Human Genetics (D.B.), Medicine (M.K.), and Pathology (J.B.H.), University of Michigan Medical School, Ann Arbor; the Parkinson School of Health Sciences and Public Health, Loyola University, Chicago (R.C., B.T.); the Department of Medicine, Boston University School of Medicine (T.O.I.), the Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School (M.R.P.), and the Departments of Pathology (B.C.) and Medicine (W.W.), Massachusetts General Hospital and Harvard Medical School - all in Boston; the Department of Medicine, College of Medicine, University of Arizona, Tucson (F.C.B.); the Departments of Biostatistics and Data Science (M.P., J.S.) and Medicine (C.I.A., J.W., A.O.), University of Kansas Medical Center, Kansas City, Kansas; and the Department of Medicine and Pediatrics, Women's College Hospital, Hospital for Sick Children and University of Toronto, Toronto (R.S.P.).

Background: Apolipoprotein L1 gene () variants are risk factors for chronic kidney disease (CKD) among Black Americans. Data are sparse on the genetic epidemiology of CKD and the clinical association of variants with CKD in West Africans, a major group in the Black population.

Methods: We conducted a case-control study involving participants from Ghana and Nigeria who had CKD stages 2 through 5, biopsy-proven glomerular disease, or no kidney disease.

View Article and Find Full Text PDF
Article Synopsis
  • The RATIONALE-301 study compared the cancer treatments tislelizumab and sorafenib in adults with unresectable hepatocellular carcinoma, finding tislelizumab met the goal of noninferiority in overall survival.
  • The research utilized various health-related quality of life (HRQOL) assessments and revealed that patients on tislelizumab reported better HRQOL outcomes, particularly in aspects of fatigue and physical functioning, compared to those on sorafenib.
  • Overall, tislelizumab not only showed better quality of life results but also had a favorable safety profile, marking it as a promising first-line treatment option for patients with hepatocellular carcinoma.
View Article and Find Full Text PDF

Adaptation of sleep to daylight saving time is slower in people consuming a high-fat diet.

iScience

September 2024

Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Adaptation of the circadian clock to the environment is essential for optimal health, well-being, and performance. Animal models demonstrate that a high-fat diet impairs circadian adaptation to advances of the light-dark cycle; it is unknown whether this occurs in humans. Utilizing a natural experiment that occurs when humans must advance their behaviors to an earlier hour for daylight saving time (DST), we measured the influence of diet on sleep/wake timing relative to dim-light melatonin onset time.

View Article and Find Full Text PDF

Glioma resection is associated with prolonged survival, but neuro-oncological trials have frequently refrained from quantifying the extent of resection. The Response Assessment in Neuro-Oncology (RANO) resect group is an international, multidisciplinary group that aims to standardise research practice by delineating the oncological role of surgery in diffuse adult-type gliomas as defined per WHO 2021 classification. Favourable survival effects of more extensive resection unfold over months to decades depending on the molecular tumour profile.

View Article and Find Full Text PDF
Article Synopsis
  • The Delphi consensus aimed to clarify management practices for abdominal aortic aneurysms (AAAs) due to conflicting data in previous literature.
  • A group of 44 experts anonymously discussed six key topics over three rounds, achieving a 100% response rate.
  • Key findings included the agreement on minimum case volume for AAA repairs, the effectiveness of screening programs, lifelong surveillance after repair, and the consideration of screening for women smokers at 65, but no consensus on certain repair thresholds or thrombosis prevention was reached.
View Article and Find Full Text PDF
Article Synopsis
  • * A consensus among medical professionals led to the creation of a standardized PSMA PET/CT reporting template, aimed at streamlining communication between radiologists and referring physicians.
  • * The proposed template includes essential details like treatment history, tumor uptake information, and incidental findings, which are intended to improve the clarity and utility of imaging reports in patient management.
View Article and Find Full Text PDF

The rise of endovascular repair for abdominal, thoracoabdominal, and thoracic aortic aneurysms.

J Vasc Surg

January 2025

Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:

Background: Given changes in intervention guidelines and the growing popularity of endovascular treatment for aortic aneurysms, we examined the trends in admissions and repairs of abdominal aortic aneurysms (AAAs), thoracoabdominal aortic aneurysms (TAAAs), and thoracic aortic aneurysms (TAAs).

Methods: We identified all patients admitted with ruptured aortic aneurysms and intact aortic aneurysms repaired in the Nationwide Inpatient Sample between 2004 and 2019. We then examined the use of open, endovascular, and complex endovascular repair (OAR, EVAR, and cEVAR) for each aortic aneurysm location (AAA, TAAA, and TAA), alongside their resulting in-hospital mortality, over time.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the effectiveness of nivolumab, an immunotherapy drug, used before and after surgery in patients with high-risk renal cell carcinoma compared to traditional surgery alone.
  • It was a randomized phase 3 trial involving 819 patients across multiple sites in the US and Canada, who were assigned to either the nivolumab plus surgery group or surgery only group.
  • The primary outcome measured was recurrence-free survival, with safety being assessed for all patients who started treatment, and the trial has been officially closed to new participants.
View Article and Find Full Text PDF

Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specifically in patients with parenchymal brain metastases, treatment options, and clinical research protocols for patients with LM from solid tumors have similarly evolved to improve survival within specific populations. Recent expansions in clinical investigation, early diagnosis, and drug development have given rise to new unanswered questions.

View Article and Find Full Text PDF

Background: There is good evidence that elevated amyloid-β (Aβ) positron emission tomography (PET) signal is associated with cognitive decline in clinically normal (CN) individuals. However, it is less well established whether there is an association between the Aβ burden and decline in daily living activities in this population. Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established.

View Article and Find Full Text PDF

Mutations in Facial-Onset Sensory and Motor Neuronopathy.

Neurol Genet

June 2024

From the Department of Neurology (V.P.-M.), Massachusetts General Hospital/Harvard Medical School; Department of Neurology (V.P.-M.), MassGeneral Institute for Neurodegenerative Diseases (MIND); Department of Neurology (S.B.), Massachusetts General Hospital; Department of Neurology (A.A.A.), Brigham Women's Hospital, Harvard Medical School, Boston, MA.

Objectives: Facial-onset sensory and motor neuronopathy (FOSMN) is a rare neuromuscular disorder characterized by progressive facial sensory impairment followed by motor dysfunction in a rostro-caudal distribution. FOSMN is clinically and pathologically associated with amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). In contrast to ALS/FTD, the genetic profile of patients with FOSMN and the role of genetic testing are poorly defined.

View Article and Find Full Text PDF

ACR Appropriateness Criteria® Screening for Abdominal Aortic Aneurysm.

J Am Coll Radiol

June 2024

Specialty Chair, Brigham & Women's Hospital, Boston, Massachusetts.

Abdominal aortic aneurysm (AAA) is a significant vascular disease found in 4% to 8% of the screening population. If ruptured, its mortality rate is between 75% and 90%, and it accounts for up to 5% of sudden deaths in the United States. Therefore, screening of AAA while asymptomatic has been a crucial portion of preventive health care worldwide.

View Article and Find Full Text PDF

Adenosine kinase inhibition protects mice from abdominal aortic aneurysm via epigenetic modulation of VSMC inflammation.

Cardiovasc Res

September 2024

Vascular Biology Center, Medical College of Georgia, Augusta University, 1460 Laney Walker Blvd, Augusta, GA 30912, USA.

Aims: Abdominal aortic aneurysm (AAA) is a common, serious vascular disease with no effective pharmacological treatment. The nucleoside adenosine plays an important role in modulating vascular homeostasis, which prompted us to determine whether adenosine kinase (ADK), an adenosine metabolizing enzyme, modulates AAA formation via control of the intracellular adenosine level, and to investigate the underlying mechanisms.

Methods And Results: We used a combination of genetic and pharmacological approaches in murine models of AAA induced by calcium chloride (CaCl2) application or angiotensin II (Ang II) infusion to study the role of ADK in the development of AAA.

View Article and Find Full Text PDF

Long-term costs to Medicare associated with endovascular and open repairs of infrarenal and complex abdominal aortic aneurysms.

J Vasc Surg

July 2024

Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:

Objective: The vast majority of patients with abdominal aortic aneurysms (AAAs) undergoing repairs receive endovascular interventions (EVARs) instead of open operations (OARs). Although EVARs have better short-term outcomes, OARs have improved longer-term durability and require less radiographic follow-up and monitoring, which may have significant implications on health care economics surrounding provision of AAA care nationally. Herein, we compared costs associated with EVAR and OAR of both infrarenal and complex AAAs.

View Article and Find Full Text PDF
Article Synopsis
  • - Recent trials indicate that PD-1-directed immunotherapy, specifically pembrolizumab, may help some patients with anal squamous cell carcinoma, but there is a need for reliable biomarkers to predict who will respond to the treatment.
  • - In a phase II clinical trial involving 32 patients, the objective response rate (ORR) to pembrolizumab was low at 9.4%, with a median progression-free survival of only 2.2 months, and most patients showed low levels of beneficial immune cells.
  • - Some patients had long-term responses to pembrolizumab, with one patient lasting over 5 years, particularly those with HPV-positive tumors and no liver metastases, but challenges remain due to ongoing HPV infection
View Article and Find Full Text PDF

Background: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced prostate cancer in an international cohort. We investigated the associations of marital status and living arrangements with OS among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer (IRONMAN).

View Article and Find Full Text PDF

Abdominal aortic aneurysm (AAA) is defined as abnormal dilation of the infrarenal abdominal aortic diameter to 3.0 cm or greater. The natural history of AAA consists of progressive expansion and potential rupture.

View Article and Find Full Text PDF

Predicting neurobehavioral performance of resident physicians in a Randomized Order Safety Trial Evaluating Resident-Physician Schedules (ROSTERS).

Sleep Health

February 2024

Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Article Synopsis
  • The study investigates how different work schedules affect the performance of resident physicians, particularly focusing on the impact of extended duty hours and sleep deprivation.
  • Using a mathematical model, researchers compared performance metrics, specifically attentional failures, between those on standard prolonged shifts and those on a rapidly cycling schedule designed to limit continuous work hours.
  • Results indicated that physicians on extended shifts experienced significantly more performance impairment, particularly at night, and that overall performance declined over time on both schedules, with a greater decline observed in those with extended hours.
View Article and Find Full Text PDF

Entrainment to gradual vs. immediate 8-hour phase advance shifts with and without short-wavelength enriched polychromatic green light.

Sleep Health

February 2024

Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital, Boston, Massachusetts, USA; Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Article Synopsis
  • The study aimed to see how different light conditions and sleep schedules impact the body’s natural circadian rhythm after advancing sleep by 8 hours.
  • Forty-three participants followed an 8-day inpatient program with five different lighting and sleep shift conditions, which included gradual and sudden adjustments.
  • Results showed that the combined use of higher illuminance white and green light with a modified shift led to the greatest advancements in melatonin onset and improved sleep quality compared to other methods.
View Article and Find Full Text PDF

Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score.

Methods: Patients with treatment-naïve unresectable HCC, ≥1 measurable untreated lesion, and Child-Pugh class A liver function were randomized 2:1 to receive atezolizumab 1,200 mg + bevacizumab 15 mg/kg every 3 weeks or sorafenib 400 mg twice daily.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatocellular carcinoma (HCC) is a major cause of cancer deaths, and there is a need for new first-line treatment options; tislelizumab, a PD-1 inhibitor, shows promise as a second-line treatment.
  • The RATIONALE-301 clinical trial compares the efficacy and safety of tislelizumab and sorafenib in treating unresectable HCC in newly diagnosed patients.
  • Results indicate that tislelizumab meets the criteria for noninferiority in overall survival compared to sorafenib, with a median overall survival of 15.9 months vs. 14.1 months; however, it did not demonstrate superiority, while showing a higher objective response rate (14.3%
View Article and Find Full Text PDF

Background: In the phase 3 ARAMIS study (NCT02200614), darolutamide significantly improved metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Following the primary analysis, the study was unblinded, and placebo recipients were permitted to cross over to open-label darolutamide. Despite crossover, darolutamide significantly improved overall survival (OS).

View Article and Find Full Text PDF

Background: Resection of the contrast-enhancing (CE) tumor represents the standard of care in newly diagnosed glioblastoma. However, some tumors ultimately diagnosed as glioblastoma lack contrast enhancement and have a 'low-grade appearance' on imaging (non-CE glioblastoma). We aimed to (a) volumetrically define the value of non-CE tumor resection in the absence of contrast enhancement, and to (b) delineate outcome differences between glioblastoma patients with and without contrast enhancement.

View Article and Find Full Text PDF